New tools are urgently needed for the detection of latent tuberculosis (TB). We evaluated the diagnostic potential of 2 novel Mycobacterium tuberculosis complex-specific candidate antigens (Rv2653 and Rv2654) and investigated T cell recognition during natural infection in humans and experimental infection in guinea pigs. Peripheral blood mononuclear cells stimulated with peptide pools covering the full length of Rv2654 induced interferon-g release in 10 of 19 patients with TB. Neither Rv2654 single peptides nor Rv2654 pools were recognized by bacille Calmette-Guérin-vaccinated donors. However, peptides from Rv2653 were recognized by both patients group. The cross-reactive epitope(s) in Rv2653 were located in a 36-amino acid stretch in the center of the molecule. Rv2654 also induced M. tuberculosis-specific skin-test responses in 3 of 4 aerosolinfected guinea pigs. Rv2654 is a strongly recognized T cell antigen that is highly specific for TB and has potential as a novel cell-mediated immunity-based TB diagnostic agent.
Tuberculosis (TB) remains one of the most urgent global health problems, with 2 million deaths and 8 million new cases annually [1] . At the same time, onethird of the total world population-2 billion peopleis believed to be latently infected with Mycobacterium tuberculosis, the etiological agent of TB. Latently infected individuals have an ∼10% lifetime risk of developing disease, and this huge global reservoir of infection and disease serves as a continuous source of transmission. To control the global epidemic, it is therefore vital to have efficient tools for the diagnosis of both the latent and active forms of pulmonary TB. Although significant progress has been made in recent years in the laboratory, the diagnosis of active pulmonary TB and latent TB has, until recently, solely been based on the tuberculin skin test (TST) with purified protein derivative (PPD) [2] . PPD contains many antigens that are widely shared among mycobacteria, and a specific diagnosis of tuberculosis based on the intradermal injection of PPD is therefore greatly complicated by the widespread use of Mycobacterium bovis bacille Calmette-Guérin (BCG) vaccines [3] . One obvious way around this problem is to use M. tuberculosis proteins that are not encoded in M. bovis BCG stains.
A genomic comparison of M. tuberculosis H37Rv and several M. bovis BCG vaccine strains recently identified
1100 such open-reading frames (ORFs) distributed in 12 regions of difference (RDs) on the chromosome [4, 5] . RD1 was lost early during the process of attenuating M. bovis BCG and is therefore missing in all daughter strains today [6] . This region has been the subject of detailed studies and has provided several candidate antigens for diagnostic and vaccine use [7] [8] [9] [10] . Antigens like early secreted antigen target (ESAT)-6 and culturefiltrate protein (CFP)-10 are located in this region and provide very interesting targets for TB diagnosis, especially given that these molecules also are absent in most atypical mycobacteria species [11] , even though they are present in a related pathogen, Mycobacterium leprae [12] . Outside RD1, only a few molecules (e.g., MPT64 encoded in RD2) have been characterized and analyzed so far [13] . In our search for new antigens with diagnostic potential, we have investigated 2 ORFs encoded in a phage-inserted region. M. tuberculosis contains 2 phage inserts, phiRv1 (RD3) and phiRv2 (RD11), which have a similar gene organization [14] . Because at least 1 of these inserts is present in Mycobacterium africanum [15] , Mycobacterium microti [16] , and several M. bovis isolates [4] but is absent in Mycobacterium canettii [15] , they are most likely the results of phage insertion into the genome of a relatively recent common ancestor of the M. tuberculosis complex. This makes proteins encoded in these inserts particularly interesting as diagnostic antigens, because, in contrast to many of the deletions in BCG, they are highly specific for the M. tuberculosis complex and are absent from atypical mycobacteria. We focused our efforts on phiRv2, because all M. bovis BCG strains tested are missing this entire insertion [4] , and the results of a recent study of samples from persons living in San Francisco indicated that phiRv2 is the genetically most stable of the 2 phage inserts in clinical isolates of M. tuberculosis [17] . In silico analysis of the 15 ORFs encoded in phiRv2 identified 2 small genesRv2653 and Rv2654-that are organized to make up a small operon with some similarity to the operon that encodes the very immunogenic antigens CFP-10 and ESAT-6 [18] . We therefore chose these 2 ORFs for immunological analysis.
MATERIALS AND METHODS

Database searches.
The Synthetic peptides. Previously, it has been demonstrated that human T cell responses to recombinant TB10.4, ESAT-6, and CFP-10 are equivalent to responses to mixtures of overlapping peptides covering the respective protein [19, 20] . A mixture of overlapping peptides covering Rv2654 and Rv2653 was therefore used as a substitute for the whole protein. Synthetic overlapping peptides (18-mer) covering the complete primary sequence of the 2 proteins were synthesized by solidphase methods (Schafer-N). For Rv2653 peptides, there was an 8-or 9-aa overlap to adjacent peptides, and, for Rv2654 peptides, there was a 5-or 6-aa overlap.
PCR detection of Rv2653 in clinical isolates. Clinical isolates of mycobacteria were grown on Middlebrook 7H10 medium at 37ЊC for 3 weeks. The bacilli were inactivated, and DNA was released by heating at 98ЊC for 1 h. The Rv2653 gene was amplified from the mycobacterial DNA using 0.4 mmol/L the oligonucleotides Rv2653F 5 -TTGACCCACAAGCGCACT-AAA-3 and Rv2653R 5 -CTGTTTGCTGTCGGGTTCGT-3 and 0.5 U of Hotstar Taq (Invitrogen) in a 50-mL reaction volume. PCRs were initiated by a 15-min 94ЊC activation/denaturation step followed by 30 cycles of denaturation (at 94ЊC for 30 s), hybridization (at 60ЊC for 30 s), and extension (at 68ЊC for 1 min) in the supplied buffer supplemented with 200 mmol/L dNTPs. The identity of the 321-bp amplified fragment was confirmed by restriction digest using AvaI. Control reactions using DNA from laboratory strains of M. bovis BCG gave no PCR product. The restriction-fragment length polymorphism (RFLP) profiles were determined as described elsewhere [21] .
Donors. The healthy BCG-vaccinated donors were all Danish-born adults aged 20-67 years who had received BCG vaccination during childhood. They all answered a questionnaire about BCG vaccination, travel history, contact with patients who had TB, and occupational exposure to mycobacteria. Donors who revealed risks for such exposure were excluded. The patients with TB (aged 18-64 years) were locally born Danish or Dutch citizens, as well as immigrants from Somalia, Pakistan, the Philippines, Vietnam, Bosnia, Iraq, Bhutan, and Venezuela. Patients had microscopy-or culture-proven infection or were clinically diagnosed on the basis of response to anti-TB treatment (2 patients). The patients were diagnosed as having pulmonary or extrapulmonary TB (TB lymphadenitis, psoas abces, and peritoneal TB), although 1 patient (clinically diagnosed) had TB of unknown origin. All participating donors gave their informed written consent, and the study was approved by the local ethical committee for Copenhagen and Frederiksberg (RH 01-282/96 and KF 01-369/98) and the local Ethical Committee of Leiden University Medical Center.
Isolation, storage, and growth of cells. Peripheral blood mononuclear cells (PBMCs) were separated from whole blood by density centrifugation, as described elsewhere [22] , and frozen in liquid nitrogen for storage. PBMCs were thawed and resuspended in complete RPMI 1640 medium (Gibco BRL, Life Technologies) supplemented with 1% penicillin/streptomycin (Gibco BRL, Life Technologies), 1% nonessential amino acids (ICN Biomedicals), and 10% heat-inactivated normal human AB serum. The viability and number of the cells were determined by Nigrosin staining.
Measurement of interferon (IFN)-g release. Cell cultures were established in triplicate with
PBMCs in 100- 5 1.25 ϫ 10 mL in microtiter plates (Nunc) and stimulated with either a total peptide concentration of 10 mg/mL when tested in pools or 10 mg/mL for each peptide when tested individually. Cell cultures without peptides were included as negative controls and PPD and phytohemagglutinin as positive controls (results not shown). After incubation for 5 days at 37ЊC (in 5% CO 2 and 95% air), supernatants were harvested, and IFN-g was detected with a standard sandwich ELISA technique using commercially available monoclonal antibodies (Endogen), according to the manufacturer's instructions. Recombinant IFN-g (Endogen) was used as a standard to quantitate IFN-g.
Guinea pigs and delayed-type hypersensitivity (DTH) responses. The Danish National animal welfare committee approved all animal experiments. Outbred female Dunkin Hartley guinea pigs (Møllegaard Breeding and Research Center) were used in the study. M. tuberculosis infection was done by the aerosol route in an exposure chamber of a Glas-Col inhalation exposure system, which was calibrated to deliver ∼20-25 M. tuberculosis Erdman bacilli into the lungs of each animal. A group of guinea pigs was injected intradermally with 6 2 ϫ 10 cfu of BCG (BCG Danish 1331; Statens Serum Institut). Skin tests were performed 28 days after infection using 2 mg of pooled Rv2653 or Rv2654 peptides, 2 mg of each of the 6 single peptides covering Rv2654 and 10 tuberculin U of PPD (1 mg), or 2 mg of recombinant ESAT-6 (as positive U p 0.02 controls). All proteins and peptides were dissolved in 0.1 mL of PBS. Skin-test responses (diameter of erythema) were independently read 24 h later by 2 experienced examiners, and the results were expressed as the mean of the 2 readings. The variation between the 2 readings was !10%. Skin-test responses 15 mm were regarded as positive.
RESULTS
Genetic polymorphism and species distribution analysis of Rv2653 and Rv2654. Recently, polymorphisms for several of the variable regions resulting from insertion-deletion events have been reported in different M. tuberculosis strains [15, 17] . We therefore investigated the presence of Rv2653 in 18 randomly selected clinical isolates of M tuberculosis isolated from Danish and foreign patients. RFLP analysis showed that the 18 clinical isolates belonged to 17 different RFLP clusters and therefore were isolated from at least 17 different clones of M. tuberculosis [21] . All 18 isolates gave the expected 321-bp DNA fragment, which indicates that none of these isolates had lost the phiRv2 insert (data not shown). Rv2653 was used as a marker for the presence of the insert-full-length Rv2654 could not be amplified from M. tuberculosis H37Rv because of secondary structure/primer hybridization problems in the PCR. Negative control reactions with 2 laboratory strains of M. bovis BCG resulted in no amplified products.
Interspecies analysis using database searches of the genomes from M. avium subspecies avium, M. avium subspecies paratuberculosis, M. marinum, M. leprae, M. smegmatis, and M. ulcerans confirmed that both genes are absent from these genomes. A general TBLASTN search against the Genbank databases without complexity filter using the full-length ORFs also came up with no homologues outside the Mycobacterium genus.
T cell recognition of Rv2653 and Rv2654 in patients with TB and BCG-vaccinated donors. The potential of Rv2653 and Rv2654 as specific diagnostic TB markers was evaluated by comparing in vitro cellular responses with pools of overlapping peptides covering the sequence of the molecules. Two pools of 3 or 5 peptides covered each molecule. PBMCs isolated from patients with TB ( ) and BCG-vaccinated donors n p 19 ( ) were stimulated in vitro, and the release of IFN-g n p 22 was measured in the supernatant. Both pools of Rv2653 peptides induced a significant release of IFN-g (1150 pg/mL) in samples from patients with TB; taken together, they identified 11 of 19 samples from patients with TB (table 1) . Six of 19 samples were from patients with pulmonary TB, and the peptide mix identified 5 of these. Recognition of the peptide pools was not specific to TB, because both pools also induced significant release of IFN-g in samples from the BCG-vaccinated group (table 1) . Rv2654, however, did not induce IFN-g release in any of the samples from the BCG-vaccinated group but did induce significant levels in 10 of 19 samples from patients with TB. Peptides 4-6 performed especially well in this study group, identifying 10 of 19 TB samples by itself-in the pulmonary TB samples in particular, the peptide pool prevailed, identifying 5 of 6 patients. Taken together, these results demonstrate that Rv2654 is a highly specific novel antigen, with the C-terminal part of the protein being especially strongly recognized by the immune system in patients with both pulmonary and nonpulmonary TB. Rv2653, on the other hand, contains у1 strongly recognized epitopes that are not unique to M. tuberculosis.
Mapping of the T cell epitopes on Rv2653 and Rv2654. To further characterize the molecules and analyze the fine specificity of the specific and cross-reactive T cell response in more detail, overlapping peptides were analyzed individually on an additional panel that consisted of PBMCs from 9 patients with TB and 30 BCG-vaccinated individuals ( figure 1A-1D ). The results with Rv2654 peptides confirmed the very high specificity of this antigen for patients with TB. No samples in the BCGvaccinated control group reacted to any of the peptides (figure 1A). Using a cutoff of 150 pg/mL IFN-g, all peptides except peptide 4 were recognized by T cells from at least 2 patients ( figure 1C ), thereby demonstrating a wide array of T cell epitopes in this molecule ( figure 1C ). Peptides 1, 2, 3, and 5 were recognized by the same 2 patient samples. The most frequently recognized peptide (peptide 4, covering aa 38-55) was recognized by T cells from 7 of 9 patients, including 3 of 4 patients with pulmonary TB. In Rv2653, the cross-reactive epitopes recognized by BCG-vaccinated donors were clearly identified in the middle region of the protein sequence, which corresponds to peptides 4-6, with peptide 6 in particular being strongly recognized in samples from 9 of 30 donors (figure 1B). These epitopes were also recognized strongly in the group of patients with TB, but, in addition, both the N-and C-terminal part of the molecule were found to contain several epitopes recognized only in patients with TB ( figure 1D ). BLAST searches using peptide 4, 5, or 6 sequences did not reveal any obvious candidate sequence from mycobacteria species that could explain the cross-reactivity found in the central part of the Rv2653 molecule. The TB patient-specific peptides-1, 7, 8, and 10-clearly identified 3, 2, 2, and 3 patient samples, respectively. Unfortunately, none of them recognized the 2 patient samples not identified by Rv2654 peptide 4. DTH responses against Rv2654 in guinea pigs. To further establish the diagnostic potential of the 2 antigens, we evaluated DTH responses to Rv2653 and Rv2654. Individual DTH responses in M. tuberculosis-infected and BCG-vaccinated guinea pigs to positive control samples and relevant peptides are shown in figure 2. As expected, PPD did not discriminate between exposure to M. tuberculosis or M. bovis BCG, whereas ESAT-6 gave very strong responses only in M. tuberculosis-infected guinea pigs, as has been reported elsewhere [7] . Rv2653 peptides tested as a pool or as single peptides gave no DTH response in TB-infected or BCG-vaccinated guinea pigs (only results from pooled peptides are shown). DTH responses to the Rv2654 peptide pool (1-6), on the other hand, were highly specific to M. tuberculosis-samples from 3 of 4 infected guinea pigs gave a positive skin-test response (induration, 15 mm), and samples from 0 of 5 BCG-vaccinated animals responded to this molecule with positive DTH responses. In the TB-infected guinea pigs, the Rv2654 mean diameter was 10 mm (SD, 3 mm), whereas the PPD response was 14 mm (SD, 2 mm). From the peptide mapping, it is clear that the response in Dunkin Hartley guinea pigs is largely caused by epitope(s) in the C-terminal part of the Rv2654 protein.
DISCUSSION
New diagnostic tests that can distinguish active and latent TB infection from BCG vaccination and environmental sensitization are urgently needed to detect and control transmission from this immense global reservoir. The TST based on PPD results in a large number of false-positive results, because M. tuberculosis, M. bovis BCG, and atypical mycobacteria share many of the immunodominant proteins that are found in PPD. Recent years have seen significant progress and a range of different approaches to the development of diagnostic tests for the diagnosis of tuberculosis, all of which are based on different ways of measuring cell-mediated immune responses induced by ongoing infection. ELISPOT, whole-blood, and PBMC-based assays for the detection of IFN-g responses to M. tuberculosisspecific antigens have both shown promise as tests for the diagnosis of patients with active culture-positive or treated TB [23] [24] [25] , as well as for the sensitive detection of latent TB [26, 27] . The classic TST is in the process of being developed into a TB-specific skin test by the use of defined purified antigens [28, 7] , but these tests, although highly specific, still have not reached an optimal diagnostic sensitivity. Therefore, one of the most ) and bacille Calmette-Guérin (BCG)-vaccinated donors ( ), after in vitro n p 9 n p 30 stimulation with the 2 panels of overlapping peptides. Peptide numbering is from the N-terminal end of the proteins; 150 pg/mL IFN-g was used as a fixed cutoff for a positive response to the peptides. The patient group included 4 patients with pulmonary and 5 patients with nonpulmonary TB.
pressing problems for developing better cell-mediated immune reaction-based diagnostic assays is the identification of new antigens that can induce a strong and TB-specific immune response.
The identification of regions in the M. tuberculosis genome that are not present in the M. bovis and M. bovis BCG genomes has opened up new opportunities for the identification of these proteins. Using subtractive hybridization, 3 regions-RD1, RD2, and RD3-were first identified as being absent from the M. bovis BCG genome. Later, with the use of DNA chips and bacterial artificial chromosome libraries, these findings were confirmed, and 13 new regions, RD4-RD16, were identified [4, 5] . For the present study, we used this knowledge and tested Rv2653 and Rv2654, 2 M. tuberculosis-specific genes that are found in a phage-inserted region (RD11) in the M. tuberculosis chromosome.
To our knowledge, prior to the present work, only 3 antigens-ESAT-6, CFP-10, and MPT64-from the RDs have been suggested as TB diagnostic proteins. MPT64 (Rv1980c) is found in RD2 that is absent in 8 of 13 tested M. bovis BCG strains [4] , making it useful but not ideal for diagnostic purposes. MPT64 discriminates ongoing TB infection in guinea pigs from BCG vaccination [29] , but its potential as a human diagnostic protein has not been clearly established. In vitro, MPT64 is only weakly recognized and induces only low levels of IFN-g release [30, 31] , and data on DTH responses have so far been contradictory [28, 30] .
ESAT-6 and CFP-10 are both encoded in RD1 and are absent from all M. bovis BCG strains tested but present in both M. tuberculosis and M. bovis, making them ideal for both human and cattle TB diagnostic tests [8] . Both proteins are well-characterized M. tuberculosis antigens, and their immunological relevance has been demonstrated in a large number of studies from different laboratories. In humans, ESAT-6 and CFP-10 give rise to a highly specific immune response in a high percentage of patients with PPD-positive TB from various ethnic groups [19, 32] , and both proteins are also major T cell targets in experimentally infected guinea pigs and cattle [33] [34] [35] .
Rv2653 and Rv2654 are found in RD11, which results from a phage insertion in the M. tuberculosis genome. Because RD11 is absent from all M. bovis BCG strains [4] and BLAST searches against available mycobacterial databases have shown that the region is absent from all environmental mycobacterial genomes searchable at present, the encoded antigens are potentially very interesting for human diagnosis. Strong T cell responses to . Individual DTH responses were read after 24 h. Erythema 15 mm was considered to be a positive response; 2 mg in total of Rv2653 and Rv2654 peptides were tested as pools, and 2 mg of each of the 6 peptides covering Rv2654 were also tested individually (P1…P6). Recombinant early secreted antigen target (rESAT)-6 was included as a positive control.
Rv2653 in samples from both patients with TB and BCG-vaccinated persons (table 1) clearly demonstrate that this antigen is immunogenic but that it apparently shares epitopes with organisms not related to M. tuberculosis, which compromises its diagnostic potential. Peptide mapping located the cross-reactive epitopes exclusively to the center of the primary sequence ( figure  1B) . The source that leads to cross-reactivity has not been identified but may be found outside of the Mycobacterium genus, because all available mycobacterial databases were carefully searched with these sequences, and nothing with a reasonable match was identified. Another example of an antigen that is encoded in the deleted regions but is not specific for M. tuberculosis at the cellular level is Mtb9.9E (Rv2346c). It was identified together with its 4 close homologues by screening a genomic library with T cell lines generated from PPD-positive donors [36] , is located in RD5, and is therefore absent from M. bovis and all M. bovis BCG strains tested [4] . Unfortunately, its 4 close homologues are all present in M. bovis BCG strains, thereby jeopardizing the diagnostic potential of this antigen. If such antigens should be considered for TB diagnosis, it will be important to remove the cross-reactive parts of the molecule. Thus, for Rv2653, it will be necessary to remove at least a continuous stretch of 22 aa in the central part of the molecule, to avoid cross-reactivity. Rv2654, on the other hand, is a clear-cut example of one of the rare, completely M. tuberculosis-specific antigens. It gives strong responses in samples from patients with both pulmonary and nonpulmonary TB (table 1) to T cell epitopes distributed throughout the entire protein ( figure 1C) , and the antigen is highly specific, because none of the samples from the 52 BCGvaccinated individuals tested, either with pools or with overlapping peptides, induced any significant IFN-g production. Given the large variation in origin of the patients with TB and, thereby, a large variation in genetic background of both the hosts and clinical mycobacterial isolates, it is quite surprising that there is such a clear main epitope in Rv2654 (peptide 4). The Rv2654 pool of peptides (peptides 4-6) identified 10 of 19 samples (sensitivity, 53%), but the Rv2654 peptide 4 alone identified 7 of 9 samples tested (sensitivity, 78%), in both cases with a specificity of 100%. Because of the relatively low number of patients in the peptide-mapping experiment, caution is needed when comparing these results, but one simple explanation for the apparently better performance of peptide 4 alone could be that the 3 times higher concentration is more optimal for the assay.
As described above, much progress has been made in the development of in vitro IFN-g release assays such as ELISPOT and QuantiFERON. However, because they require fresh blood, it is difficult for practical and logistical reasons to see these being implemented on a large scale in the developing world during the near future. Therefore, it would be desirable if new antigens also could be used as a replacement for PPD in future skin tests. Rv2654 indeed gave strong responses in 3 of 4 guinea pigs, with the DTH-inducing epitope found in peptide 6, the C-terminal part of the protein.
The fact that Rv2654 has a large number of human T cell epitopes and can induce a DTH reaction in guinea pigs (3/4) is encouraging for the practical application of Rv2654 in a diagnostic test, especially given the similarities it shares with ESAT-6 and CFP-10. Genetic variability in populations of bacteria is well known [37] , and, for mycobacteria, many large insertions and deletions have been identified. Even though the Rv2653 gene is found in all 18 clinical isolates tested in the present work, it has recently been reported that some clinical isolates have lost the phiRv2 region [15, 17] .
Such genetic instability of large regions in bacterial genomes clearly illustrates that most antigens from single chromosomal regions cannot stand alone as diagnostic reagents but have to be supplemented with antigens from other regions to obtain broad coverage. Even though ESAT-6 and CFP-10 perform ex-tremely well in diagnostic tests with sensitivities of 60%-80%, the results can still be improved [31, 32, 38] , but it is essential that this does not compromise the high specificity of the test. We have demonstrated that the strong cell-mediated immune responses against Rv2654 are highly specific, making it a very useful supplement in a diagnostic protein mixture. We have recently initiated large-scale studies to precisely determine how much Rv2654 adds in terms of sensitivity to the already established diagnostic antigens. Hopefully, with the panel of highly specific antigens available, an accurate diagnostic test for the detection of latent TB is within reach.
